US 8268847

US patent 8268847, titled "Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor", was issued to Actelion Pharmaceuticals Ltd on September 18, 2012. The patent was filed on August 28, 2007, under application number US12/439,290, and lists Martine Clozel as the inventor.

The abstract describes the invention as a product combining a specific compound (of formula I), which is an endothelin receptor antagonist, with at least one compound having PDE5-inhibitory properties. This combination, including pharmaceutically acceptable salts of both compounds, is intended for therapeutic use—either simultaneously, separately, or over a period of time—in the treatment of diseases where vasoconstriction is a factor.

Plain-Language Overview of Independent Claims:

• Claim 1: This claim protects a product that includes a specific endothelin receptor antagonist (represented by formula I) and a PDE5 inhibitor. This combined product is for use in treating diseases characterized by constricted blood vessels, and the components can be administered together, separately, or sequentially over time.
• Claim 6: This claim covers a pharmaceutical composition containing, as its active ingredients, the specific endothelin receptor antagonist (of formula I) and a PDE5 inhibitor, along with at least one inactive component (excipient).
• Claim 10: This claim describes a method of treatment for patients suffering from hypertension or pulmonary hypertension. The method involves administering an effective dose of the specific endothelin receptor antagonist (of formula I) in combination with a PDE5 inhibitor.

No active CAFC dockets for US8268847 in 2026 were identified through the search. The patent information does indicate a PTAB case, IPR2025-01139, which was filed but not instituted on procedural grounds.